opioids

FDA black box warning: combined CNS depression at GABA-A and mu-opioid receptors causes profound respiratory depression, coma, and death.

Avoid concurrent use. If absolutely necessary in supervised settings, lowest doses, shortest duration, monitor respiratory rate and oxygen saturation. Naloxone availability.

Source: Kimi deep-research + Cla

FDA black box warning: combined use of benzodiazepines and opioids causes profound respiratory depression, coma, and death via synergistic CNS depression at different receptor sites (GABA-A and mu-opioid).

Avoid concurrent use. If absolutely necessary in supervised settings, limit to lowest doses, shortest duration, monitor respiratory rate and oxygen saturation, and ensure naloxone availability.

Source: Kimi deep-research + Cla

Additive CNS/respiratory depression

Avoid (boxed warning class)

Source: Kimi deep-research + Cla

Profound sedation, respiratory depression, coma, and potentially death. Concomitant use significantly increases the risk of overdose and death.

Avoid concomitant use if possible. If co-administration is necessary, prescribe the lowest effective doses and shortest durations possible. Monitor patients closely for signs of respiratory depression and sedation. Educate patients and caregivers about the risks. Consider naloxone availability.

Additive respiratory depression, sedation, coma, death; FDA black box warning

Avoid concurrent use if possible; if unavoidable, monitor respiratory rate closely and have naloxone available

Source: Kimi deep-research + Cla

Profound CNS depression, including severe sedation, respiratory depression, coma, and potentially death. Increased risk of opioid overdose.

Avoid co-administration if possible. If unavoidable, use the lowest effective doses of both drugs for the shortest duration possible. Monitor closely for respiratory depression and sedation. Consider naloxone availability. Educate patients and caregivers on the risks.

Additive CNS/respiratory depression

Avoid combination; boxed warning class

Source: Kimi deep-research + Cla

Pharmacodynamic synergy causing respiratory depression. Gabapentin + opioids significantly increase risk of opioid-induced respiratory depression, sedation, and death. FDA issued warning December 2019.

Avoid concurrent use if possible. If necessary, use lowest effective doses of both, limit duration, and monitor closely for sedation and respiratory depression. Consider naloxone availability.

Source: Kimi deep-research + Cla

Additive respiratory depression, sedation, coma, death; FDA black box warning

Avoid concurrent use if possible; if unavoidable, monitor respiratory rate closely and have naloxone available

Source: Kimi deep-research + Cla

Profound additive respiratory depression/sedation (boxed)

Avoid combination; if essential lowest doses, monitored setting, naloxone/flumazenil ready

Source: Kimi deep-research + Cla

Additive CNS/respiratory depression

Avoid combination (boxed warning class)

Source: Kimi deep-research + Cla

Additive CNS and respiratory depression. Pregabalin and opioids both depress central respiratory drive. Concurrent use significantly increases risk of profound sedation, respiratory depression, coma, and death, particularly in elderly or opioid-naive patients.

Avoid concurrent use if possible. If combination is necessary, use lowest effective doses of both agents, monitor respiratory rate closely (target ≥10 breaths/min), and consider naloxone availability. Start with reduced opioid dose (25-50% less) and titrate cautiously.

Source: Kimi deep-research + Cla